Showing 1801-1810 of 7598 results for "".
Guselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.Recognizing Dermatologic Emergencies in Kids
https://practicaldermatology.com/conferences/scale-2023/recognizing-dermatologic-emergencies-in-kids/20198/Infections including congenital infections, syphilis, or HSV are the No. 1 cause of pediatric skin emergencies. Infantile hemangiomas in the airway can affect breathing and also require fast and early treatment, explains Thy Huynh, MD.Clinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts diEducational Excellence
https://practicaldermatology.com/series/dermatology-education-foundation/educational-excellence/19994/The excellent faculty and top-notch education are the highlights of Dermatology Education Foundation conferences, says Kara S. Gooding, MMS, PA-C.Stay Relevant with Education
https://practicaldermatology.com/series/dermatology-education-foundation/stay-relevant-with-education/19989/Feed yourself new information and stay on top of data regarding new and existing medications in order to offer patients the best care possible, says Wendy Cantrell, CRNP, DNP. This is particularly important as new understanding of conditions like psoriasis and atopic dermatitis evolve and new treatmNew Topical Options for Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-topical-options-for-psoriasis/19979/Leon Kircik, MD shares his excitement about new molecules for psoriasis. He discusses the available data for tapinarof, a first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, and roflumilast cream, a once-daily topical formulation of roflumilast, a highScientifically Speaking: Diagnosing and Treating Hair Loss, Part 1
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-diagnosing-and-treating-hair-loss-part-1/19954/Hair loss is distressing for many patients. The first step in management is to identify the cause of hair loss, modify contributing factors, and develop an effective treatment plan. Host Joel L. Cohen, MD discusses the challenges of managing hair loss with Marc Avram, MD, Cheryl Burgess, MD, and ReeDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiStraight Scoop: Audience Questions Answered
https://practicaldermatology.com/topics/practice-management/straight-scoop-audience-questions-answered/19820/The panelists respond to questions from the audience about negotiating, choosing opportunities, and even how to say "No" the right way.COVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditi